Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Laurie H. Sehn, Alex F. Herrera, Matthew J. Matasar, Manali Kamdar, Andrew K. McMillan, Tae Min Kim, Won Seog Kim, Mark Hertzberg, Muhit Ozcan, Elicia Penuel, Ji Cheng, Jamie M. Hirata, Grace Ku and Christopher Flowers | ||||||||||||
Title | Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study | ||||||||||||
|
|||||||||||||
URL | http://www.bloodjournal.org/content/130/Suppl_1/2821 | ||||||||||||
Abstract Text | Blood 2017 130 (Suppl 1):2821 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|